Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $17.25.

A number of equities research analysts recently issued reports on ENTA shares. Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. HC Wainwright decreased their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Finally, JMP Securities reissued a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at $35,000. US Bancorp DE lifted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the period. Quest Partners LLC grew its position in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after buying an additional 9,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals during the third quarter valued at about $122,000. Finally, Valence8 US LP acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

ENTA opened at $5.75 on Thursday. The company has a market capitalization of $121.87 million, a PE ratio of -1.05 and a beta of 0.49. The business has a 50-day moving average of $8.72 and a 200-day moving average of $11.32. Enanta Pharmaceuticals has a fifty-two week low of $5.30 and a fifty-two week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. During the same quarter last year, the firm earned ($1.33) earnings per share. Enanta Pharmaceuticals’s revenue was down 22.8% compared to the same quarter last year. On average, equities research analysts expect that Enanta Pharmaceuticals will post -4.73 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.